Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases

Deng, Ya; Zhang, Xudong; Shen, Haibin; He, Qiangnan; Wu, Zijian; Liao, Wenzhen; Yuan, Miaomiao

doi:10.3389/fbioe.2019.00489

Cited by 169 publications

(67 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanomaterials have been explored as drug delivery carriers for localized and controlled delivery of drugs to the target site. In cardiovascular medicine, conventional drugs or novel synthetic compounds are delivered to reduce atherosclerotic lesion formation, promote angiogenesis in ischemic tissues and improve the remodelling process in the damaged organs [ [68] , [69] , [70] ]. In the emerging area of nanotechnology, carbon allotropes are considered as one of the cardinal classes, which have gained significant attention in drug delivery applications [ 71 , 72 ].…”

Section: Application Of Cnms In Cardiovascular Tissue Engineeringmentioning

confidence: 99%

Carbon nanomaterials for cardiovascular theranostics: Promises and challenges

Alagarsamy

Mathan

Yan

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Heart attack and stroke cause irreversible tissue damage. The currently available treatment options are limited to “damage-control” rather than tissue repair. The recent advances in nanomaterials have offered novel approaches to restore tissue function after injury. In particular, carbon nanomaterials (CNMs) have shown significant promise to bridge the gap in clinical translation of biomaterial based therapies. This family of carbon allotropes (including graphenes, carbon nanotubes and fullerenes) have unique physiochemical properties, including exceptional mechanical strength, electrical conductivity, chemical behaviour, thermal stability and optical properties. These intrinsic properties make CNMs ideal materials for use in cardiovascular theranostics. This review is focused on recent efforts in the diagnosis and treatment of heart diseases using graphenes and carbon nanotubes. The first section introduces currently available derivatives of graphenes and carbon nanotubes and discusses some of the key characteristics of these materials. The second section covers their application in drug delivery, biosensors, tissue engineering and immunomodulation with a focus on cardiovascular applications. The final section discusses current shortcomings and limitations of CNMs in cardiovascular applications and reviews ongoing efforts to address these concerns and to bring CNMs from bench to bedside.

show abstract

Section: Application Of Cnms In Cardiovascular Tissue Engineeringmentioning

confidence: 99%

Carbon nanomaterials for cardiovascular theranostics: Promises and challenges

Alagarsamy

Mathan

Yan

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

show abstract

“…As evident from earlier studies, nano-based theranostics were found to influence the prognosis of atherosclerosis, angiogenesis and other CVDs by sensitive detection of pathophysiological conditions and also infer appropriate therapeutic measures [ 124 ]. The efficacy of nanotheranostics in CVDs lies in the early and sensitive detection of CVDs associated with pathophysiology, controlled and localized drug delivery, and prolonged therapeutic effect [ 125 ].…”

Section: Limitations and Future Perspectivesmentioning

confidence: 99%

Nanomaterials as Novel Cardiovascular Theranostics

et al. 2021

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are a group of conditions associated with heart and blood vessels and are considered the leading cause of death globally. Coronary heart disease, atherosclerosis, myocardial infarction represents the CVDs. Since CVDs are associated with a series of pathophysiological conditions with an alarming mortality and morbidity rate, early diagnosis and appropriate therapeutic approaches are critical for saving patients’ lives. Conventionally, diagnostic tools are employed to detect disease conditions, whereas therapeutic drug candidates are administered to mitigate diseases. However, the advent of nanotechnological platforms has revolutionized the current understanding of pathophysiology and therapeutic measures. The concept of combinatorial therapy using both diagnosis and therapeutics through a single platform is known as theranostics. Nano-based theranostics are widely used in cancer detection and treatment, as evident from pre-clinical and clinical studies. Nanotheranostics have gained considerable attention for the efficient management of CVDs. The differential physicochemical properties of engineered nanoparticles have been exploited for early diagnosis and therapy of atherosclerosis, myocardial infarction and aneurysms. Herein, we provided the information on the evolution of nano-based theranostics to detect and treat CVDs such as atherosclerosis, myocardial infarction, and angiogenesis. The review also aims to provide novel avenues on how nanotherapeutics’ trending concept could transform our conventional diagnostic and therapeutic tools in the near future.

show abstract

“…While a few other physical stimuli such as light, heat, and ultrasound have been proposed or implemented for treating these conditions, shear stress as a mechanical trigger has the advantage of being endogenous and site‐specific to the bleeding or pathological location. [ 27–29 ] This review provides a critical literature survey of research from the past decade on shear‐triggered nanocarriers for drug delivery. This review will primarily focus on the formulations of the nanosystems and their shear response mechanisms, as opposed to previous reviews which focus more on the physiological and translational aspects of shear‐sensitive DDSs.…”

Section: Introductionmentioning

confidence: 99%

Recent Developments in Nanomaterial‐Based Shear‐Sensitive Drug Delivery Systems

Wang

Pisapati

Zhang

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Nanomaterial‐based drug delivery systems (DDSs) increase the efficacy of various therapeutics, and shear stress has been shown to be a robust modulator of payload release. In the past few decades, a deeper understanding has been gained of the effects of flow in the body and its alteration in pathological microenvironments. More recently, shear‐responsive nanomaterial DDSs have been developed. Studies on this subject mainly from the last decade are reviewed here, focusing on innovations of the material design and mechanisms of the shear response. The two most popular shear‐controlled drug carriers distinguished by different release mechanisms, that is, shear‐deformable nanoparticles (NPs) and shear‐dissociated NP aggregates (NPAs), are surveyed. The influence of material structures on their properties such as drug loading, circulation time, and shear sensitivity are discussed. The drug development stages, therapeutic effects, limitations, and potential of these DDSs are further inspected. The reviewed research emphasizes the advantages and significance of nanomaterial‐based shear‐sensitive DDSs in the field of targeted drug delivery. It is also believed that efforts to rationally design nanomaterial DDSs responsive to shear may prompt a new class of diagnostics and therapeutics for signaling and rectifying pathological flows in the body.

show abstract

Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases

Cited by 169 publications

References 169 publications

Carbon nanomaterials for cardiovascular theranostics: Promises and challenges

Carbon nanomaterials for cardiovascular theranostics: Promises and challenges

Nanomaterials as Novel Cardiovascular Theranostics

Recent Developments in Nanomaterial‐Based Shear‐Sensitive Drug Delivery Systems

Contact Info

Product

Resources

About